Acorda Therapeutics Up 8.8% On Sales News (ACOR)

Shares of Acorda Therapeutics, Inc. (Nasdaq: ACOR) are trading up 8.8% at $30.09 per share during the Monday afternoon trading session.

The company announced on Monday morning that its AMPYRA (dalfampridine) Extended Release Tablets, reached 4th quarter sales of $55.7 million and that its Zanaflex Capsules (tizanidine hydrochloride) had $15.8 million in sales.

President and CEO Ron Cohen said, “AMPYRA is the first medication indicated to improve walking in people with multiple sclerosis, a critical need in this disease. More than 31,000 patients received a prescription in the first seven months of commercial availability, underscoring AMPYRA's utility in addressing this previously unmet need. The successful launch of AMPYRA provides a solid base on which to continue building value in our company, through increased trial of AMPYRA by appropriate patients, advancing our product pipeline and acquiring clinical stage compounds to complement our existing assets.”

The day's range for shares of Acorda Therapeutics, Inc has been between $28.27 and $30.21 per share.

The average price target of analysts who cover Acorda Therapeutics, Inc. (ACOR) is $33.58 per share.

Volume of 1.6 million shares is already more than double the daily average volume of 773,000 shares.

Acorda Therapeutics, Inc is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders.

Read more from Benzinga's Company news.